Key facts
- This page summarizes Jonathan Mark Hopper's Form 4 filing for Vericel Corp (VCEL).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 26 Feb 2024, 16:05.
Jonathan Mark Hopper - 22 Feb 2024 Form 4 Insider Report for Vericel Corp (VCEL)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- VCEL
- Reported as of
- 22 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 26 Feb 2024, 16:05:36 UTC
- Prior SEC filing
- 22 Feb 2024
- Next SEC filing
- 21 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sean Flynn, as Attorney-in-Fact for Jonathan Hopper
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Jonathan Mark Hopper filed Form 4 for Vericel Corp (VCEL) on 26 Feb 2024.
Change
- Previous filing in this sequence was filed on 22 Feb 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VCEL
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +30,000
- Change %
- Price
- $0.000000
- Shares after
- 30,000
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 30,000
- Exercise price
- $48.31
- Footnotes
- F1
VCEL
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +12,000
- Change %
- Price
- $0.000000
- Shares after
- 12,000
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 12,000
- Exercise price
- Footnotes
- F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
These options shall begin vesting on February 22, 2024 and shall continue to vest and become exercisable in equal quarterly installments over the course of the following four (4) year period.
Footnote F2
Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation.
Footnote F3
These RSUs vest in four annual installments with the initial vesting of RSUs granted to the Reporting Person on February 22, 2025. The remaining RSUs will vest in annual installments on February 22, 2026, February 22, 2027, and February 22, 2028, respectively.
Footnote F4
No expiration date for this type of award.